The immune profile of small HER2-positive breast cancers: a secondary analysis from the APT trial-Reference-Cited by-同舟云学术

The immune profile of small HER2-positive breast cancers: a secondary analysis from the APT trial

Published:2019-04 Issue:4 Volume:30 Page:575-581
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Barroso-Sousa R.,Barry W.T.,Guo H.,Dillon D.,Tan Y.B.,Fuhrman K.,Osmani W.,Getz A.,Baltay M.,Dang C.,Yardley D.,Moy B.,Marcom P.K.,Mittendorf E.A.,Krop I.E.,Winer E.P.,Tolaney S.M.

Funder

Genentech

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/30/4/575/28565015/mdz047.pdf

Reference30 articles.

1. Characteristics of HER2-positive breast cancer diagnosed following the introduction of universal HER2 testing;Pathmanathan;Breast,2012

2. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene;Slamon;Science,1987

3. Natural and therapy-induced immunosurveillance in breast cancer;Kroemer;Nat Med,2015

4. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial;Loi;Annals of Oncology,2014

5. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy;Denkert;Lancet Oncol,2018

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2-Positive Breast Cancer;JAMA Oncology;2024-05-01

2. Predictive Markers of Treatment Response to Neoadjuvant Systemic Therapy with Dual HER2-Blockade;Cancers;2024-02-19

3. Predictive markers of treatment response to neoadjuvant systemic therapy with dual HER2-blockade;2024-01-02

4. Clinical characteristics and treatment outcomes of HER2 mutation and HER2 fusion in 22 patients with advanced breast cancer;Thoracic Cancer;2023-10-20

5. Real-world clinical outcomes of patients with stage I HER2-positive breast cancer treated with adjuvant paclitaxel and trastuzumab;Critical Reviews in Oncology/Hematology;2023-10